Denileukin diftitox
| Clinical data | |
|---|---|
| Trade names | Ontak |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a611024 |
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Elimination half-life | 70-80 min |
| Identifiers | |
| |
| CAS Number | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C2560H4042N678O799S17 |
| Molar mass | 57647.3 g/mol g·mol−1 |
  (what is this?) (verify) | |
Denileukin diftitox (trade name Ontak) was an antineoplastic agent, an engineered protein combining Interleukin-2 and Diphtheria toxin. Denileukin diftitox could bind to Interleukin-2 receptors[1] and introduce the diphtheria toxin into cells that express those receptors, killing the cells. In some Leukemias and Lymphomas malignant cells express these receptors, so denileukin diftitox can target these.
In 1999 Ontak was approved by the U.S. Food and Drug Administration (FDA) for treatment of Cutaneous T-cell lymphoma (CTCL).[2]
There is some evidence tying it to vision loss and in 2006 the FDA added a black box warning to the drug's label.[2]
In 2014 marketing of Ontak was discontinued in the US.[3]
References
- ^ Turturro F (2007). "Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders". Expert Rev Anticancer Ther. 7 (1): 11–7. doi:10.1586/14737140.7.1.11. PMID 17187516.
- ^ a b FDA Page Last Updated: May 11, 2009 Changes in the Ontak (denileukin diftitiox) Package Insert to Include a Description of Ophthalmologic Adverse Events
- ^ "FDA Drug Shortages". FDA. 31 January 2014. Retrieved 3 July 2017.
External links
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |